Hashimoto's vs Graves' Disease: A Practical Comparison Checklist

Diagnostic Checklist: Antibody Profiles and Laboratory Markers

The laboratory distinction between these conditions centers on autoantibody patterns that reflect opposite immune mechanisms. Hashimoto's typically shows elevated thyroid peroxidase antibodies (TPOAb) in 90-95% of cases and thyroglobulin antibodies (TgAb) in 60-80%, marking destructive autoimmunity. Graves' disease presents with thyroid-stimulating immunoglobulins (TSI) or thyrotropin receptor antibodies (TRAb) in 95-98% of untreated patients, driving receptor overstimulation. Both may show elevated TPOAb, but the functional receptor antibody defines Graves'.

Thyroid function tests diverge predictably: Hashimoto's progresses from subclinical hypothyroidism (elevated TSH, normal free T4) to overt hypothyroidism (high TSH, low free T4). Graves' shows suppressed TSH with elevated free T4 and free T3, often with a T3-to-T4 ratio exceeding 20:1 in thyrotoxicosis. Radioactive iodine uptake (RAIU) separates them further—low in Hashimoto's thyroiditis, diffusely elevated in Graves'. These patterns hold across populations, though antibody titers correlate imperfectly with disease severity.

A practical checklist for initial workup ensures neither condition is missed when presentations overlap, such as in hashitoxicosis or during treatment transitions.

• Order TSH, free T4, free T3 simultaneously—establishes baseline thyroid status and calculates T3/T4 ratio
• Measure TPOAb and TgAb—positive in most Hashimoto's; supportive but not diagnostic for Graves'
• Request TSI or TRAb—functional receptor antibodies confirm Graves'; negative makes Graves' unlikely
• Consider RAIU scan if diagnosis uncertain—diffuse high uptake supports Graves'; low uptake suggests thyroiditis
• Check thyroglobulin level—often elevated in both but disproportionately high in destructive thyroiditis

Clinical Presentation Checklist: Symptom Patterns by Disease Phase

Symptom clusters reflect the underlying thyroid hormone state rather than the autoimmune process itself. Hashimoto's manifests as hypothyroid symptoms: fatigue, cold intolerance, weight gain despite reduced appetite, constipation, dry skin, hair thinning, menstrual irregularities, and cognitive slowing. These develop insidiously over months to years. A subset experiences transient thyrotoxicosis (hashitoxicosis) during acute inflammatory destruction, mimicking Graves' with palpitations, heat intolerance, and anxiety—but without ophthalmopathy or diffuse goiter vascularity.

Graves' presents with thyrotoxic symptoms: weight loss despite increased appetite, heat intolerance, tremor, tachycardia, anxiety, insomnia, frequent bowel movements, and muscle weakness. Distinctive extrathyroidal features include Graves' ophthalmopathy (proptosis, periorbital edema, diplopia) in 25-50% and pretibial myxedema (localized dermal thickening) in 1-5%. These stigmata never occur in Hashimoto's. Goiter in Graves' is typically diffuse, soft, and often audible with a bruit; Hashimoto's goiter tends to be firm, irregular, and non-vascular.

Symptom checklists must account for age-related attenuation—older adults often present with apathetic thyrotoxicosis or isolated atrial fibrillation rather than classic hyperadrenergic signs.

• Document weight trajectory with appetite context—gain with poor appetite suggests hypothyroidism; loss with hunger suggests thyrotoxicosis
• Assess heart rate and rhythm at rest—persistent tachycardia or new atrial fibrillation warrants thyroid evaluation
• Examine eyes for lid lag, stare, proptosis, conjunctival injection—specific to Graves' ophthalmopathy
• Palpate thyroid for size, consistency, vascularity—diffuse soft goiter with bruit favors Graves'; firm irregular goiter favors Hashimoto's
• Inspect pretibial skin for non-pitting edema—pathognomonic for Graves' dermopathy
• Screen for muscle weakness patterns—proximal myopathy in thyrotoxicosis; slow relaxation reflexes in hypothyroidism

Demographic and Geographic Risk Checklist: Who Develops Which Condition

Both conditions show strong female predominance, but the magnitude differs. Hashimoto's affects women 8-10 times more often than men, typically diagnosed between ages 30-50. Graves' shows a 5-7:1 female-to-male ratio with peak incidence 20-40 years. The gender gap narrows after menopause for Hashimoto's but persists for Graves'. Genetic susceptibility overlaps—HLA-DR3 associates with both, while HLA-DR5 links more specifically to Hashimoto's. First-degree relatives of affected individuals carry 5-15% lifetime risk for either condition, with concordance higher in monozygotic twins (30-40% for Graves', 20-30% for Hashimoto's).

Geographic and ethnic variation reveals environmental modulation. Iodine-sufficient regions show higher Hashimoto's prevalence (1-2% of population) versus iodine-deficient areas where goitrous Hashimoto's predominates. Graves' incidence rises with iodine repletion programs—the Jöd-Basedow phenomenon. East Asian populations demonstrate lower Graves' rates but similar Hashimoto's frequencies compared to Caucasian groups. African ancestry correlates with lower autoantibody positivity rates but more severe thyrotoxicosis when Graves' occurs. Smoking doubles Graves' risk and worsens ophthalmopathy, while showing a paradoxical protective association with Hashimoto's.

A risk assessment checklist helps identify patients warranting proactive screening, particularly during high-trigger periods.

• Female sex, age 20-50—highest risk window for both conditions
• Family history of autoimmune thyroid disease—screen first-degree relatives with TSH every 1-2 years
• Personal history of other autoimmune conditions—type 1 diabetes, celiac, vitiligo, rheumatoid arthritis increase risk 3-5 fold
• Recent iodine exposure—contrast media, amiodarone, kelp supplements can trigger either condition
• Smoking status—current smokers: prioritize Graves' and ophthalmopathy screening; former smokers: elevated Hashimoto's risk persists 10+ years post-cessation
• Postpartum period—screen TSH at 3 and 6 months postpartum; 5-10% develop transient thyroiditis
• Ethnic background consideration—adjust pre-test probability for Graves' in East Asian patients; consider more severe thyrotoxicosis presentation in African ancestry patients

Treatment Decision Checklist: Therapeutic Pathways by Category

Treatment algorithms diverge fundamentally: Hashimoto's requires hormone replacement; Graves' requires hormone reduction. Levothyroxine dosing for Hashimoto's targets TSH normalization (0.4-4.0 mIU/L), typically 1.6 mcg/kg daily, adjusted by age, weight, cardiac status, and pregnancy. Overtreatment risks iatrogenic thyrotoxicosis and bone loss. Graves' management offers three definitive pathways: antithyroid drugs (methimazole preferred, propylthiouracil in first trimester), radioactive iodine ablation (RAI), or thyroidectomy. Choice depends on age, goiter size, antibody titers, ophthalmopathy severity, patient preference, and regional expertise. Remission rates with 12-18 months of antithyroid drugs range 30-50% in iodine-sufficient areas but drop below 20% in high-iodine regions.

Special categories demand tailored approaches. Pediatric Graves' favors antithyroid drugs as first-line due to RAI theoretical malignancy concerns, though recent data reassure. Elderly patients with comorbidities often receive RAI for definitive control. Pregnancy requires propylthiouracil in weeks 6-16 (lower teratogenicity), then methimazole; RAI is contraindicated. Hashimoto's in pregnancy needs levothyroxine dose increases of 25-50% by 4-6 weeks gestation. Both conditions require careful perioperative management—thyroid storm prophylaxis for Graves', hypothyroidism optimization for Hashimoto's.

A treatment selection checklist ensures guideline-concordant decisions while incorporating patient values and local resource availability.

• Confirm diagnosis before initiating definitive therapy—avoid empirical treatment for indeterminate cases
• Assess Graves' severity markers: TRAb level, goiter size, ophthalmopathy grade, age—high titers, large goiter, moderate-severe eye disease predict antithyroid drug failure
• Evaluate RAI candidacy: age > 40-50, small goiter, no active ophthalmopathy, non-pregnant, compliance with radiation precautions
• Consider surgery for: large compressive goiter, suspicious nodules, moderate-severe ophthalmopathy (RAI may worsen), patient preference, rapid definitive control needed
• For Hashimoto's: initiate levothyroxine if TSH > 10 mIU/L, or TSH 4.5-10 with symptoms/antibodies/goiter/pregnancy/cardiac risk factors
• Set pregnancy-specific TSH targets: < 2.5 mIU/L first trimester, < 3.0 mIU/L second/third trimesters—adjust levothyroxine preemptively
• Plan monitoring intervals: Hashimoto's—TSH at 6-8 weeks post-dose change, then annually; Graves' on antithyroid drugs—TSH, free T4, LFTs every 4-6 weeks initially

Monitoring and Long-Term Management Checklist

Long-term surveillance differs in focus but shares principles: hormone optimization, complication detection, and comorbidity screening. Hashimoto's monitoring centers on TSH stability—annual checks once euthyroid, more frequent with dose changes, pregnancy, medications affecting absorption (calcium, iron, PPIs), or weight shifts. Levothyroxine requirements may decline with age or increase with autoimmune progression. Atrophic thyroiditis develops in 10-15% after decades, necessitating dose escalation. Cardiovascular risk assessment includes lipid profiling, as subclinical hypothyroidism elevates LDL cholesterol.

Graves' remission monitoring requires TRAb tracking—persistently elevated titers after antithyroid drug cessation predict relapse (60-80% at 1 year if TRAb positive vs 20-30% if negative). Post-RAI or post-surgical patients transition to Hashimoto's-like monitoring for hypothyroidism, typically developing within 3-6 months after RAI and immediately after total thyroidectomy. Ophthalmopathy follows an independent course—activity scoring (CAS) every 3-6 months during active phase, then annually. Smoking cessation remains the single most impactful modifiable factor for eye disease progression.

A unified monitoring checklist captures both conditions' evolving needs while preventing gaps during care transitions.

• TSH monitoring schedule: Hashimoto's—annual if stable; Graves' post-ablation—every 4-6 weeks until stable, then 6 monthly, then annually
• TRAb measurement: at Graves' diagnosis, at antithyroid drug cessation decision point, and if relapse suspected—guides remission prediction
• Ophthalmopathy assessment: Clinical Activity Score (CAS) every 3 months if active; orbital MRI if optic neuropathy suspected
• Bone density screening: baseline DEXA for postmenopausal women and men > 50 with history of thyrotoxicosis or overtreatment; repeat per guidelines
• Cardiovascular risk: lipid panel annually for Hashimoto's; atrial fibrillation screening for elderly Graves' patients
• Comorbidity surveillance: celiac serology (TTG-IgA) at diagnosis for both; type 1 diabetes screening if symptomatic; adrenal insufficiency screen if autoimmune polyglandular syndrome suspected
• Medication interaction review at each visit: calcium, iron, PPIs, H2 blockers, cholestyramine, estrogen, anticonvulsants affect levothyroxine absorption
• Pregnancy planning: preconception TSH optimization, TRAb assessment for Graves' (predicts neonatal thyrotoxicosis risk), medication adjustment protocol

Pregnancy and Reproductive Health Checklist

Thyroid autoimmunity profoundly impacts fertility and pregnancy outcomes, with distinct implications for each condition. Hashimoto's associates with infertility, recurrent miscarriage, and preterm delivery even when euthyroid, likely through TPOAb-mediated placental inflammation. TPOAb-positive euthyroid women have 2-3 fold higher miscarriage rates. Levothyroxine treatment in TPOAb-positive women with TSH > 2.5 mIU/L reduces miscarriage and preterm birth. Graves' in pregnancy carries risks of maternal thyrotoxicosis, fetal/neonatal thyrotoxicosis from TRAb transplacental passage (1-5% of neonates), and postpartum thyroiditis flare. TRAb levels > 3-5 times upper limit predict neonatal thyrotoxicosis requiring treatment.

Trimester-specific management differs. First trimester: propylthiouracil preferred for Graves' (lower teratogen risk than methimazole), with switch at week 16. TSH targets tighten: < 2.5 mIU/L first trimester, < 3.0 thereafter. Levothyroxine doses often increase 30-50% by 6-8 weeks gestation. Postpartum: both conditions flare—Hashimoto's may present as destructive thyrotoxicosis followed by hypothyroidism; Graves' often relapses 3-6 months postpartum. Breastfeeding is compatible with all standard therapies at appropriate doses—methimazole < 20 mg/day, propylthiouracil < 300 mg/day, levothyroxine unrestricted.

A reproductive health checklist ensures critical windows aren't missed and fetal-neonatal risks are mitigated.

• Preconception: optimize TSH < 2.5 mIU/L for Hashimoto's; achieve euthyroidism on lowest antithyroid drug dose for Graves'
• Confirm pregnancy immediately—repeat TSH, free T4, TRAb at 4-6 weeks gestation
• Switch propylthiouracil to methimazole at 16 weeks gestation if on antithyroid drugs
• Monitor TSH/free T4 every 4 weeks until 20 weeks, then every 6-8 weeks—adjust medications promptly
• Measure TRAb at 20-24 weeks if Graves' history—levels > 3x ULN warrant neonatal monitoring plan
• Fetal ultrasound for goiter, tachycardia, growth restriction if maternal TRAb elevated or uncontrolled thyrotoxicosis
• Postpartum: check TSH at 6 weeks and 3-6 months—high flare risk for both conditions
• Breastfeeding counseling: all standard thyroid medications compatible; infant monitoring if maternal antithyroid drugs used

Comorbidity Screening Checklist: Associated Autoimmune Conditions

Autoimmune thyroid diseases rarely exist in isolation. Hashimoto's clusters with type 1 diabetes (15-30% coexistence), celiac disease (4-8% vs 1% general population), vitiligo, alopecia areata, pernicious anemia, and Addison's disease. Screening yields actionable findings: celiac diagnosis explains refractory hypothyroidism (malabsorption) and improves levothyroxine absorption on gluten-free diet. Pernicious anemia causes macrocytic anemia and neurological symptoms. Addison's disease, though rare (0.5%), creates life-threatening adrenal crisis risk if thyroid replacement starts before glucocorticoids—the cortisol requirement for thyroid hormone metabolism unmasks insufficiency.

Graves' shares the celiac and type 1 diabetes associations but adds unique linkages: myasthenia gravis (5-10% of Graves' patients have acetylcholine receptor antibodies), rheumatoid arthritis, and systemic lupus erythematosus. The thymus connection—thymic hyperplasia in Graves', thymoma association with myasthenia—suggests shared T-cell dysregulation. Pretibial myxedema and acropachy signal more severe autoimmune diathesis. Polyglandular autoimmune syndrome type 2 (Schmidt syndrome) combines Hashimoto's or Graves' with Addison's and/or type 1 diabetes; type 3 combines thyroid autoimmunity with other organ-specific conditions excluding adrenal.

Systematic comorbidity screening at diagnosis and periodically thereafter prevents missed diagnoses that complicate thyroid management.

• Celiac serology (TTG-IgA, total IgA) at diagnosis for both conditions—repeat if symptoms develop
• Type 1 diabetes screening: fasting glucose/HbA1c at diagnosis, then annually if antibodies positive (GAD65, IA-2, ZnT8)
• Pernicious anemia workup: B12, methylmalonic acid, intrinsic factor antibodies if macrocytosis or neuropathy
• Adrenal function: morning cortisol/ACTH if fatigue disproportionate to thyroid status, hypotension, hyperpigmentation, electrolyte abnormalities—critical before levothyroxine initiation
• Vitiligo/alopecia areata: skin/hair examination at each visit—clinical diagnosis, no serology needed
• Myasthenia gravis screen: acetylcholine receptor antibodies if Graves' with unexplained fatigable weakness, diplopia, ptosis
• Rheumatologic panel: ANA, RF, anti-CCP if joint symptoms, rash, sicca symptoms—baseline at diagnosis for Graves'
• Repeat screening every 2-3 years or with new symptoms—autoimmune conditions accumulate over decades